Get the Stockscreener App
14.20
7.45%
0.91
Uniqure N V stock is traded at $14.20, with a volume of 1.15M.
It is up +7.45% in the last 24 hours and up +4.23% over the past month.
See More
Previous Close:
$13.29
Open:
$13.82
24h Volume:
1.15M
Relative Volume:
0.88
Market Cap:
$495.88M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-2.1914
EPS:
-6.48
Net Cash Flow:
$-153.08M
1W Performance:
+47.98%
1M Performance:
+4.23%
6M Performance:
+114.74%
1Y Performance:
+196.27%
1-Day Range:
$13.46
$14.31
1-Week Range:
$8.95
$14.98
52-Week Range:
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
14.19 | 495.88M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.69 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.23 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.69 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.00 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.09 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
(QURE) Investment Analysis - news.stocktradersdaily.com
UniQure stock holds $70 target, buoyed by FDA breakthrough nod - Investing.com India
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Yahoo Finance
uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold - Seeking Alpha
uniQure: Bullish On Near Term Catalysts After Breakthrough Therapy Designation For AMT-130 - Seeking Alpha
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting - Seeking Alpha
uniQure jumps on FDA breakthrough tag for Huntington’s disease drug - MSN
AMT-130 gets FDA breakthrough therapy designation - European Biotechnology Magazine
FDA grants breakthrough status to uniQure’s Huntington’s therapy By Investing.com - Investing.com Canada
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic By Stocktwits - Investing.com India
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic - MSN
UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington's Disease Treatment - RagingBull
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? - Benzinga
uniQure (QURE) Surges After FDA Grants Breakthrough Status to Gene Therapy - GuruFocus
uniQure stock jumps on FDA breakthrough tag (QURE:NASDAQ) - Seeking Alpha
uniQure (QURE) Revenue and EPS Fall Short of Expectations - GuruFocus
uniQure shares soar on FDA breakthrough therapy designation By Investing.com - Investing.com South Africa
uniQure shares soar on FDA breakthrough therapy designation - Investing.com
FDA grants breakthrough status to uniQure’s Huntington’s therapy - Investing.com
uniQure (QURE) Secures Breakthrough Therapy Status for AMT-130 | QURE Stock News - GuruFocus
UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation - marketscreener.com
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease | QURE Stock News - GuruFocus
Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease - TradingView
uniQure N.V. Receives FDA Breakthrough Therapy Designation for AMT-130 in Huntington's Disease Treatment - Nasdaq
uniQure Announces FDA Breakthrough Therapy Designation - GlobeNewswire
Revolutionary Gene Therapy for Huntington's Disease Earns FDA Breakthrough Status After Promising Trial Results - Stock Titan
uniQure (NASDAQ:QURE) Shares Sold by Vanguard Group Inc. - Defense World
Hemophilia B Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme Sanofi - Barchart.com
uniQure CEO secures amended employment agreement By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Buys 58,246 Shares of uniQure (NASDAQ:QURE) - Defense World
uniQure CEO secures amended employment agreement - Investing.com
uniQure Amends CEO Employment Agreement - TipRanks
Alliancebernstein L.P. Has $3.60 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World
NEVADA KING ANNOUNCES INCREASE OF PHASE III PROGRAM TO 30,000M, REFINES REGIONAL TARGETS AT ATLANTA - The Globe and Mail
Institutional owners may ignore uniQure N.V.'s (NASDAQ:QURE) recent US$190m market cap decline as longer-term profits stay in the green - simplywall.st
(QURE) Long Term Investment Analysis - news.stocktradersdaily.com
uniQure (NASDAQ:QURE) Now Covered by Analysts at Chardan Capital - The AM Reporter
Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval - insights.citeline.com
Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com
Stock Watch: Are Gene Therapy Prices Too High For Success? - insights.citeline.com
(QURE) Trading Report - Stock Traders Daily
uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World
Oppenheimer & Co. Inc. Buys New Stake in uniQure (NASDAQ:QURE) - Defense World
FY2025 Earnings Estimate for uniQure Issued By HC Wainwright - Defense World
uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright - Defense World
uniQure CFO Christian Klemt sells $107,407 in shares By Investing.com - Investing.com Australia
uniQure Reports 2024 Financial Results and Progress - TipRanks
uniQure’s chief medical officer sells shares worth $13,891 - Investing.com India
uniQure CFO Christian Klemt sells $107,407 in shares - Investing.com India
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure N V Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '25 |
Sale |
10.29 |
10,438 |
107,407 |
217,730 |
| Potts Jeannette | Chief Legal Officer |
Mar 04 '25 |
Sale |
10.29 |
7,076 |
72,812 |
119,743 |
| Kapusta Matthew C | CEO, Managing Director |
Feb 25 '25 |
Sale |
10.70 |
26,727 |
285,979 |
571,188 |
| Kapusta Matthew C | CEO, Managing Director |
Feb 27 '25 |
Sale |
11.32 |
6,717 |
76,036 |
580,795 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Feb 25 '25 |
Sale |
10.70 |
14,341 |
153,449 |
152,372 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Feb 27 '25 |
Sale |
11.32 |
2,916 |
33,009 |
155,168 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Option Exercise |
14.71 |
100,000 |
1,471,000 |
697,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Sale |
15.03 |
100,000 |
1,503,000 |
597,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 09 '24 |
Sale |
7.63 |
3,418 |
26,079 |
597,915 |
1.75%
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):